rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Allarity Therapeutics, Inc.

ALLR · Nasdaq

Health CareBiotechnologyNot moving yet

ALLR stood above a rising 150-day average in 14 of the last 52 weekly readings, and has been out of that trend for the last 6 weeks. It is 30.5% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 6
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
18 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 14 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders18+4 on the quarter
New · exited6 · 2
Reported value$1.6M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026331,509$428K+103,425+45.3%
VANGUARD CAPITAL MANAGEMENT LLCunchanged · filed 13 Aug 2026171,795$222K00.0%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026154,867$200K-35,526−18.7%
STATE STREET CORPunchanged · filed 7 Aug 2026137,600$178K00.0%
Militia Capital Management LLCnew · filed 12 Aug 202698,978$128K+98,978
CITADEL ADVISORS LLCnew · filed 14 Aug 202691,748$118K+91,748
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 202674,913$97K00.0%
NORTHERN TRUST CORPreduced · filed 13 Aug 202636,534$47K-11,569−24.1%
JANE STREET GROUP, LLCnew · filed 14 Aug 202636,021$46K+36,021
TWO SIGMA INVESTMENTS, LPunchanged · filed 14 Aug 202627,492$35K00.0%
30 Jun 2024 – 30 Jun 2026
51117Jun 24Dec 24Jun 25Dec 25Jun 26

Everyone who traded it

Jeremy R. Graff Company insiderOfficer · last 30 Sep 20260 · 0
Gerald W. McLaughlin Company insiderDirector · last 28 Jan 20260 · 0
Jeffrey S. Ervin Company insiderCFO · last 28 Jan 20260 · 0
Thomas Jensen Company insiderCEO · last 28 Jan 20260 · 0
Jesper Hoeiland Company insiderDirector · last 7 Jan 20260 · 0
Alexander Epshinsky Company insiderCFO · last 22 Jan 20250 · 0
Joseph Walter Vazzano Company insiderDirector · last 22 Jan 20250 · 0
Laura Benjamin Company insiderDirector · last 22 Jan 20250 · 0

Same industry

MRNA ModernaLeading+147%
IOVA Iovance BiotherapeuticsLeading+126%
ABCL AbCellera BiologicsLeading+60%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+38%
ENTX Entera BioLeading+37%
HELP Helus PharmaLeading+36%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-128%
Share count trendFY 2025 · to 30 Mar 2026-1.6%
Cash and equivalentsFY 2025 · to 31 Dec 2025$14.7M
Free cash flowFY 2025 · to 31 Dec 2025−$14.8M

Analyst forecasts

No analyst forecasts yet.